Leukemia Research
Volume 28, Issue 12 , Pages 1255-1262 , December 2004

Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay

  • Iman Jilani

      Affiliations

    • Department of Hematopathology, Nichols Institute, Quest Diagnostics, 33608 Ortega Highway, Rm#108B, San Juan Capistrano, CA 92690-6130, USA
    • ,
  • Michael Keating

      Affiliations

    • Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    • ,
  • Francis J. Giles

      Affiliations

    • Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    • ,
  • Susan O’Brien

      Affiliations

    • Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    • ,
  • Hagop M. Kantarjian

      Affiliations

    • Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    • ,
  • Maher Albitar

      Affiliations

    • Department of Hematopathology, Nichols Institute, Quest Diagnostics, 33608 Ortega Highway, Rm#108B, San Juan Capistrano, CA 92690-6130, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 949 728 4784; fax: +1 949 728 4990; (mobile: +1 949 275 7564).

Received 1 December 2003 ,Accepted 1 April 2004.

References 

  1. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, et al.  Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983;62:873–882
  2. Hale G, Swirsky D, Waldmann H, Chan LC. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone-marrow transplantation. Br. J. Haematol. 1985;60:41–48
  3. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82:807–812
  4. Kirchhoff C. CD52 is the ‘major maturation-associated’ sperm membrane antigen. Mol Hum Reprod. 1996;2:9–17
  5. Focarelli R, Francavilla S, Francavilla F, Della Giovampaola C, Santucci A, Rosati F. A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa. Mol. Hum. Reprod. 1999;5:46–51
  6. Treumann A, Lifely MR, Schneider P, Ferguson MA. Primary structure of CD52. J. Biol. Chem. 1995;270:6088–6099
  7. Hale G. The CD52 antigen and development of the Campath antibodies. Cytotherapy. 2001;3:137–143
  8. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd JC, et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561
  9. Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, et al.  Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol. 1997;15:2667–2672
  10. Pawson R, Matutes E, Brito-Babapulle V, Maljaie H, Hedges M, Mercieca J, et al.  Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia?. Leukemia. 1997;11:1009–1013
  11. Ferrajoli A, O’Brien S, Kurzock R, Giles F, Williams M, Thomas D, et al.  Phase II clinical trial of Campath-1H in refractory hematological malignancies expressing the surface antigen CD52. Proc. Am. Soc. Clin. Oncol. 2000;19:8a; Abstract 22
  12. Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, et al.  CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26:69–76
  13. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakbarti S, Robinson S, et al.  In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425
  14. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, et al.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078
  15. Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol. 1993;84:542–544
  16. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet. 1993;341:1620–1622
  17. Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, et al.  Treatment of refractory Wegeners’s granulomatosis with humanized monoclonal antibodies. QJM. 1996;89:903–912
  18. Killick SB, Marsh JC, Hale G, Waldmann H, Kelly SJ, Gordon-Smith EC. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br. J. Haematol. 1997;97:306–308
  19. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy. 2001;3:261–267
  20. Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J. Immunol. Methods. 2002;260:285–302
  21. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323–327
  22. Keating M, O’Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Sem. Oncol. 2000;27:86–90
  23. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 2001;19:2153–2164
  24. Manshouri T, Giles F, O’Brien S, Cortes J, Thomas D, Kantarjian H, Keating MJ. Soluble CD52 is detectable in the plasma of patients with chronic lymphocytic leukemia, Blood 149a, 2001. Abstract 629.

PII: S0145-2126(04)00127-4

doi: 10.1016/j.leukres.2004.04.003

Leukemia Research
Volume 28, Issue 12 , Pages 1255-1262 , December 2004

Article Tools

* Image Usage & Resolution